Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in the Treatment of Children, Adolescents and Adults With Mild to Moderate Atopic Dermatitis
Conditions
Interventions
Difamilast
Locations
63
United States
Qualmedica Research, LLC
Birmingham, Alabama, United States
AllerVie Health
Birmingham, Alabama, United States
Elite Clinical Studies, LLC
Phoenix, Arizona, United States
NEA Baptist Clinic-Dermatology
Jonesboro, Arkansas, United States
First OC Dermatology
Fountain Valley, California, United States
Center for Dermatology Clinical Research, Inc.
Fremont, California, United States
Start Date
September 15, 2022
Primary Completion Date
July 31, 2024
Completion Date
July 31, 2024
Last Updated
August 9, 2024
NCT06461897
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
Lead Sponsor
Acrotech Biopharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions